T&R Biofab wins FDA 510(k) clearance for TnR CI, a 3D-printed PCL/beta-TCP biodegradable cranial implant

T&R Biofab, a South Korean biofabrication company, has received FDA 510(k) clearance for TnR CI, a 3D-printed biodegradable cranial implant. The device is a composite of polycaprolactone (PCL) and beta-tricalcium phosphate (beta-TCP), printed into an interconnected porous scaffold intended to support bone ingrowth before resorbing in the body. It is indicated for reconstructing burr holes, craniotomy incisions and other cranial defects, and for restoring or augmenting skull bony contour after neurosurgery. The FDA clearance followed review of biological safety, chemical characterization, nonclinical performance and GLP animal-study data establishing substantial equivalence to devices already marketed in the US.

Resorbable PCL/ceramic composite scaffolds are a known category in craniofacial reconstruction, but 510(k) clearance is still the gating step that lets a device reach US hospitals, and for a mid-sized Korean biofabrication company it is a meaningful market-access milestone rather than a novel materials claim. The clearance builds on a US patent T&R Biofab secured in May 2026 covering the same implant, giving the company both IP protection and regulatory standing in its target market before it lines up commercial partners. It also reflects a broader pattern of Korean AM-adjacent medical device makers using the substantial-equivalence pathway, rather than a full PMA, to enter the US market by matching an established predicate rather than proving a new mechanism from scratch. Medical and dental applications remain among the fastest-qualifying AM verticals precisely because predicate devices like this exist.

The clearance itself does not create revenue: T&R Biofab said its next step is securing US distribution and sales partners, which will determine actual hospital adoption and surgeon uptake. Reimbursement coding, neurosurgeon relationships and inventory logistics with a US partner are now the binding constraints, not further regulatory work. Investors and competitors should treat this as a market-entry ticket for the US, not yet evidence of commercial scale.